

# WIB for Business

## WIB for Business - Partner in the Development of Biomedical Innovation and Technology Commercialisation

**The Virtual Research Institute (WIB)** offers biotechnology and pharmaceutical companies, CROs, investors and business support institutions access to innovative R&D projects, biomedical technologies and opportunities for collaboration in commercialisation, technology transfer and acceleration.

---

### Virtual Research Institute - an ecosystem for biomedical innovation

**The Virtual Research Institute (WIB)** is a programme that combines long-term funding for biomedical research with tangible support for the commercialisation of innovative technologies. Powered by leading Polish research teams and operated by Łukasiewicz - PORT, WIB is a trusted partner for organisations across biotech, pharma, medtech and investment sectors.

WIB focuses on projects with the highest implementation potential - from new drugs and advanced therapies, through diagnostic technologies, to innovative solutions in personalised medicine. It is a space where science meets industry, creating projects ready to enter the domestic and global markets.

---

### Collaboration with biotechnology and pharmaceutical companies

**Biotech** and **pharmaceutical** companies gain access to R&D projects developed under a stable, long-term funding model. WIB guarantees the reliability of results, continuity of work, and a high level of scientific and technological validation.

#### Access to innovative R&D projects ready for commercialization

Business benefits:

- access to innovative biomedical technologies with high implementation potential,
- the opportunity to license solutions and engage in co-development,
- projects with confirmed quality of preclinical data,
- support in assessing technology readiness level (TRL) and preparing the translation pathway,
- connections to an ecosystem of experts, laboratories, and industry partners.

WIB is an attractive source of new technologies for companies seeking mature, innovative biomedical projects that can enhance their research or commercial portfolios.

## **Technology licensing and co-development partnerships**

### **WIB for CROs and clinical research centers**

The maturity of solutions developed within WIB means that projects naturally reach the stage of preparation for **clinical trials**. This creates extensive opportunities for collaboration with:

- CROs,
- hospitals and clinical centers,
- operators of early-phase research infrastructure.

### **What WIB offers clinical partners:**

- a pipeline of technologies ready for inclusion in Phase I/II trials,
- scientific teams prepared for regulatory and clinical collaboration,
- transparent quality, process, and preclinical documentation,
- compliance with EMA/FDA requirements in the early stages of development.

This guarantees CROs access to a stable source of innovative projects, and clinical centers—participation in the development of new therapies and diagnostics.

---

## **WIB for investors, VC/CVC funds, and business ecosystem institutions**

WIB generates projects with high investment potential, ideal for:

- VC and CVC funds,
- industry investors (biotech, medtech, pharma),
- institutions supporting innovation development,
- deep-tech ecosystem initiatives.

## **High-value investment projects, spin-off creation, and deep-tech development**

The program provides investors with:

- access to projects with low technological risk (thanks to expert verification),
- transparency in the research process and reporting,
- project readiness for spin-off creation,
- professional support in preparing for scaling and commercialization.

WIB serves as a bridge between science and business, facilitating technology transfer and the development of innovative entities in the life sciences sector.

---

## **Acceleration of medical innovations - domestic and international cooperation**

Łukasiewicz - PORT actively develops partnerships with domestic and international **acceleration programs**, incubators, and funds supporting innovation.

### **Acceleration programs in Poland and abroad**

In this area, WIB offers:

- preparation of projects for acceleration in Poland and abroad,
- a network of international industry and commercial partners,
- access to public and private funding sources,

As a result, technologies developed within WIB reach the maturity required for commercialization more quickly.

### **Development of technological, clinical, and business maturity (TRL/CRL/BRL)**

- Development of competencies in the **technological, clinical, business, and regulatory** areas,
  - Mentoring provided by experts from the life sciences, venture capital, and industrial sectors.
  - Support in developing market entry strategies and regulatory plans
- 

## **Why partner with WIB?**

- A pipeline of biomedical innovations with high market potential.
- Long-term, stable funding for R&D projects.
- Supervision by national and international experts.
- Operator experience - Łukasiewicz - PORT as a center for commercialization and technology transfer.

- Synergy between science, business, investors, and clinical partners.
- Implementation-oriented approach - every WIB project has a commercial goal.

WIB is a place where technologies that will change the future of medicine are developed—open to collaboration with business partners at every stage of innovation development.

## **Key benefits for business**

- Biomedical technology pipeline
  - High-quality R&D data
  - Access to experts and infrastructure
  - Process security and transparency
  - Ecosystem supporting commercialization
- 

## **Contact us and find out how we can work together to develop biomedical innovations**

**e-mail:** [wib\\_komercjalizacja@port.lukasiewicz.gov.pl](mailto:wib_komercjalizacja@port.lukasiewicz.gov.pl)

**tel:** + 48 71 73 47 668

**Author:**wib8 **Publish:**28.05.2026 